We found that no statistically significant difference in tumor growth between anti-BTLA or anti-PD-L1 mAbs alone and control group, whereas combined treatment with anti-BTLA and anti-PD-L1 mAbs resulted in slower tumor growth than treatment with anti-BTLA or anti-PD-L1 mAbs alone (Figures 2B, C). Here, BTLA is linked to neoplasm.